Hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) constitute ~70% of all breast malignancies and display substantial pathological and molecular heterogeneity, which impact treatment response and prognosis [1–3]. Here, ERBB2 is linked to breast cancer.